| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026 |
| 30 Sep 2026 |
8-K: Other Events
On September 30, 2026, Jade Biosciences, Inc. (“Jade”) announced preclinical data characterizing JADE301, its anti-interferon beta (“IFN-ß”) monoclonal antibody in development for dermatomyositis (“DM”), a rare, chronic and debilitating ... |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy |
| 01 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
On June 29, 2026, Jade Biosciences, Inc. (the “Company”) entered into a License Agreement (the “JADE301 License Agreement”) with Paragon Therapeutics, Inc. (“Paragon”), pursuant to which Paragon granted the Company a royalty-bearing, wor... |
| 26 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
San Francisco and Vancouver, British Columbia, June 26, 2026 — Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases,... |
| 11 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Section 1.1 Registered Office. The registered office of Jade Biosciences, Inc., a Nevada corporation (the “Corporation”), shall be the street address of the Corporation’s registered agent in the State of Nevada, as determined from time t... |
| 04 Jun 2026 |
8-K: Other Events
Introductory. Jade Biosciences, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 10,000,000 shares of its common stock, par value ... |
| 01 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
JADE101 Phase 1 Interim Data Conference Call June 1, 2026 Nasdaq: jbio Exhibit 99.1 |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress |
| 22 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 02 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 06 Mar 2026 |
8-K: Results of Operations and Financial Condition
JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027 |
| 05 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference |
| 15 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 13, 2025, by and among Jade Biosciences, Inc., a Nevada corporation (the “Company”), and each of the Persons listed on Exhibit A attached to this Agreement (ea... |
| 14 Nov 2025 |
8-K: Results of Operations and Financial Condition; Other Events
To the Board of Directors and Stockholders of Jade Biosciences, Inc. |
| 07 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 6, 2025, by and among Jade Biosciences, Inc., a Nevada corporation (the “Company”), and each of the Persons listed on Exhibit A attached to this Agreement (each... |
| 09 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition
Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy |
| 01 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more
San Francisco and Vancouver, British Columbia, July 1, 2025 — Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment ... |
| 14 May 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition +1 more
Includes related party amount of $26.0 and $22.7 million at March 31, 2025 and December 31, 2024, respectively. |
Loading...